By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Angiotensin receptor blockers > Valsartan > Valsartan Dosage
Angiotensin receptor blockers
https://themeditary.com/dosage-information/valsartan-dosage-7176.html

Valsartan Dosage

Drug Detail:Valsartan (Valsartan [ val-sar-tan ])

Drug Class: Angiotensin receptor blockers

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Congestive Heart Failure

Initial dose: 40 mg orally twice a day
Maintenance dose: 80 to 160 mg twice a day. The dose should be increased to the highest dose tolerated by the patient.

Usual Adult Dose for Hypertension

Initial dose: 80 to 160 mg orally once a day.
Maintenance dose: 80 to 320 mg orally once a day

Usual Adult Dose for Myocardial Infarction

Initial dose: 20 mg orally twice a day
Maintenance dose: The initial dosage may be titrated upward within 7 days to 40 mg twice daily, with subsequent titrations to a target maintenance dose of 160 mg twice a day as tolerated by the patient. If symptomatic hypotension or renal dysfunction occurs, consideration should be given to a dosage reduction.

Comment: Valsartan may be initiated as early as 12 hours after a myocardial infarction, and may be given with other standard postmyocardial infarction treatment, including thrombolytics, aspirin, beta blockers, and statins.

Usual Pediatric Dose for Hypertension

6 to 16 years:
Initial dose: 1.3 mg/kg once a day (up to 40 mg)
Maintenance dose: up to 2.7 mg/kg (up to 160 mg) once a day titrated according to patient response

Comments:

  • If the calculated dosage does not correspond to the available tablet strengths, or if children are unable to swallow tablets, the use of a suspension (which can be prepared from the tablets) is recommended. The valsartan dose may need to be increased if the suspension is replaced by a tablet.
  • No data are available in pediatric patients either undergoing dialysis or with a glomerular filtration rate less than 30 mL/min.

Renal Dose Adjustments

CrCl less than 30 mL/min: not recommended: Dose adjustments may be required; however, no specific guidelines have been suggested. Caution is recommended.

Pediatric patients 6 to 16 years:
CrCl less than 30 mL/min: Not recommended

Comment:

  • Pediatric patients with hypertension where underlying renal abnormalities may be more common, renal function and serum potassium should be closely monitored as clinically indicated.

Liver Dose Adjustments

Mild to moderate liver disease: No dosage adjustment recommended
Severe liver disease: Data unavailable

Dose Adjustments

Doses may be increased every 4 weeks up to 320 mg orally per day or a diuretic may be added. Adding a diuretic may be more effective than increasing the dose beyond 80 mg orally per day. Doses should be reduced in the presence of intravascular volume depletion.

Precautions

US BOXED WARNING:

  • PREGNANCY: The use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Adverse effects may include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, valsartan should be discontinued as soon as possible.

Safety and effectiveness have not been established in pediatric patients less than 6 years of age.

Dialysis

Valsartan is not removed by hemodialysis.

No data are available in pediatric patients either undergoing dialysis or with a glomerular filtration rate less than 30 mL/min/1.73 m2.

Other Comments

Administration advice:

  • Valsartan should be taken consistently either with or without food.

General:
  • The maximal antihypertensive effects of valsartan are usually achieved 4 weeks after initiation of therapy.
  • Compared with Caucasian patients, Black patients have a reduced blood pressure response to monotherapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers; however, the reduced response is largely eliminated if combination therapy that includes an adequate dose of a diuretic is instituted.

Patient advice:
  • Advice women not to breastfeed during treatment with this drug.
  • Advise patients that lightheadedness can occur, especially during the first days of treatment, and that it should be reported to their healthcare provider.
  • Advise patients to discontinue this drug until a physician has been consulted if syncope occurs.
  • Inform patients that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure.
  • Advise patients not to use salt substitutes without first consulting their healthcare provider.

Frequently asked questions

  • Losartan vs Valsartan - What's the difference between them?
  • What is the strength of Prexxartan (valsartan) oral solution?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by